Researchers in Purdue University’s College of Pharmacy are further developing a potential immunotherapy treatment for cancer, one focused on the mutation of the PTPN22 enzyme.
The National Comprehensive Cancer Network published NCCN Guidelines for Patients: Graft-Versus-Host Disease, weeks after Orencia became the first drug approved by FDA for the prevention of GVHD (The Cancer Letter, Dec. 17, 2021).
The National Comprehensive Cancer Network has published updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer.
A three-drug combination could help patients with aggressive forms of blood cancer achieve longer cancer remission after undergoing allogeneic stem cell transplantation, according to preliminary clinical trial results presented by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
According to the results of the ZUMA-7 clinical trial, the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and Opdivo (nivolumab) doubled the progression-free survival benefit compared to Opdivo alone, with a manageable safety profile, according to results of the phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center.
Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy survived longer without cancer growth than patients with insufficient dietary fiber intake, according to research from The University of Texas MD Anderson Cancer Center.
A phase II trial investigating the anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone as a first-line treatment for people with PD-L1-positive metastatic non-small cell lung cancer showed that the combination improved progression-free survival.
A University of Toronto-led study found that only 59% of oncology clinical trials studied provided adequately-defined rules for censoring.
Researchers at Penn Medicine have illuminated key molecular details of the T-cell exhaustion process, identifying a specific strategy for making chimeric antigen receptor (CAR) T cell-therapy more effective against solid tumors.
